Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dectin-1 (beta-glucan receptor, CLEC7A) is a type II transmembrane pattern recognition receptor of the C-type lectin receptor (CLR) family, primarily expressed on myeloid cells such as macrophages, dendritic cells, neutrophils, and some T cells. It specifically recognizes beta-1,3- and beta-1,6-linked glucans found in fungal cell walls as well as some bacterial polysaccharides. Upon ligand binding, Dectin-1 initiates intracellular signaling involving its hemITAM motif, resulting in the activation of innate immune responses, cytokine release, phagocytosis, and trained immunity (a form of innate memory). Dectin-1 activity is central to antifungal host defense and has been implicated in immunomodulation related to infection, inflammation, and cancer. Multiple forms of beta-glucan act as agonists and experimental modulators, but no approved small molecule drugs directly target Dectin-1. Dectin-1 works cooperatively with Toll-like receptors to shape the immune response; its expression and function are key investigative biomarkers and potential therapeutic targets in infectious and inflammatory diseases. If a different or more general “immune cell receptor for beta-glucan” were meant (such as CR3 or scavenger receptors), context indicates Dectin-1 is by far the most established and canonical receptor for this query.
Binding of beta-glucan ligands to Dectin-1 activates intracellular signaling via a hemITAM motif, leading to production of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6), ROS generation, and co-stimulation of T cells. Requires synergy with Toll-like receptor (TLR) signaling for full activation.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dectin-1 (beta-glucan receptor) (Dectin-1).